deferoxamine has been researched along with oxidopamine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ben-Shachar, D; Eshel, G; Finberg, JP; Youdim, MB | 1 |
| Davison, AJ; Gee, P | 1 |
| Bandy, B; Davison, AJ | 1 |
| Ben-Shachar, D; Eshel, G; Finberg, JP; Riederer, P; Youdim, MB | 1 |
| De Wit, LE; Gramsbergen, JB; Korf, J; Koster, JF; Sloot, WN | 1 |
| Glinka, Y; Tipton, KF; Youdim, MB | 2 |
| Becker, G; Berg, D; Grote, C; Mäurer, M; Rausch, WD; Riederer, P; Wesemann, W | 1 |
| Borisenko, GG; Hsia, CJ; Kagan, VE; Schor, NF | 1 |
| Chen, SY; Sulik, KK | 1 |
| Bandy, B; Davison, AJ; Moon, J; Walter, PB | 1 |
| Ben Shachar, D; Stephenson, G; Youdim, MB | 1 |
| Blat, D; Fridkin, M; Zheng, H | 1 |
| Haleagrahara, N; Ponnusamy, K; Siew, CJ | 1 |
| Arneson, LC; Crow, JM; Faltesek, KA; Fine, JM; Forsberg, AC; Frey, WH; Hanson, LR; Mohan, KG; Renner, DB; Wong, JC | 1 |
| Cui, X; Jiang, F; Li, Z; Liu, J; Lv, H; Niu, Y; Wang, L; Wang, W; Yu, S; Yuan, J; Zhang, H | 1 |
| Bandyopadhyay, J; Gowrishetty, KK; Mishra, S; Priyam, A; Rakshit, J | 1 |
| Applová, L; Franz, KJ; Hašková, P; Homola, P; Jansová, H; Roh, J; Šimůnek, T; Vávrová, K | 1 |
19 other study(ies) available for deferoxamine and oxidopamine
| Article | Year |
|---|---|
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Deferoxamine; Dopamine; Homovanillic Acid; Hydroxydopamines; Iron Chelating Agents; Male; Nerve Degeneration; Neurons; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1991 |
Intermediates in the aerobic autoxidation of 6-hydroxydopamine: relative importance under different reaction conditions.
Topics: Aerobiosis; Catalase; Chemical Phenomena; Chemistry; Deferoxamine; Edetic Acid; Formates; Free Radicals; Glucose; Hydrogen Peroxide; Hydroxides; Hydroxydopamines; Hydroxyl Radical; Mannitol; Metals; Oxidation-Reduction; Oxidopamine; Pentetic Acid; Superoxide Dismutase; Superoxides | 1989 |
Interactions between metals, ligands, and oxygen in the autoxidation of 6-hydroxydopamine: mechanisms by which metal chelation enhances inhibition by superoxide dismutase.
Topics: Adenosine Diphosphate; Catalase; Chelating Agents; Deferoxamine; Edetic Acid; Histidine; Hydrogen-Ion Concentration; Hydroxydopamines; Ligands; Metals; Oxidation-Reduction; Oxidopamine; Oxygen; Phytic Acid; Superoxide Dismutase | 1987 |
The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
Topics: Animals; Deferoxamine; Dominance, Cerebral; Ferritins; Free Radicals; Humans; Hydrogen Peroxide; Hydroxides; Hydroxyl Radical; Injections, Intraventricular; Iron; Lipid Peroxidation; Nitric Oxide; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Stereotyped Behavior; Substantia Nigra | 1993 |
Manganese-induced hydroxyl radical formation in rat striatum is not attenuated by dopamine depletion or iron chelation in vivo.
Topics: Animals; Corpus Striatum; Deferoxamine; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Iron; Iron Chelating Agents; Male; Manganese; Molecular Weight; Neurotoxins; Osmolar Concentration; Oxidopamine; Rats; Rats, Wistar; Reserpine; Time Factors | 1996 |
Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine.
Topics: Animals; Antioxidants; Brain; Deferoxamine; Enzyme Activation; Iron; Male; Mitochondria; NADH Dehydrogenase; Oxidopamine; Rats; Rats, Sprague-Dawley | 1996 |
Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine.
Topics: Animals; Brain; Deferoxamine; Enzyme Inhibitors; Male; Mitochondria, Liver; Oxidation-Reduction; Oxidopamine; Quinone Reductases; Rats; Rats, Sprague-Dawley | 1998 |
Iron accumulation in the substantia nigra in rats visualized by ultrasound.
Topics: Animals; Deferoxamine; Dose-Response Relationship, Drug; Ferritins; Humans; Iron; Oxidopamine; Parkinson Disease; Pilot Projects; Rats; Rats, Wistar; Substantia Nigra; Ultrasonography; Zinc | 1999 |
Interaction between 6-hydroxydopamine and transferrin: "Let my iron go".
Topics: Animals; Ascorbic Acid; Behavior, Animal; Deferoxamine; Electron Spin Resonance Spectroscopy; Ferric Compounds; Ferrozine; Free Radicals; Humans; Hydroxyl Radical; Injections, Intraperitoneal; Iron; Iron Chelating Agents; Male; Mice; Mice, Inbred A; Oxidopamine; Transferrin | 2000 |
Iron-mediated free radical injury in ethanol-exposed mouse neural crest cells.
Topics: Animals; Cell Survival; Cells, Cultured; Deferoxamine; Ethanol; Free Radicals; Iron; Mice; Mice, Inbred C57BL; Neural Crest; Oxidopamine; Phenanthrolines | 2000 |
Reaction of oxygen with 6-hydroxydopamine catalyzed by Cu, Fe, Mn, and V complexes: identification of a thermodynamic window for effective metal catalysis.
Topics: Adenosine Diphosphate; Bromides; Buffers; Catalysis; Copper; Deferoxamine; Edetic Acid; Histidine; Hydrogen-Ion Concentration; Iron; Ligands; Manganese; Osmolar Concentration; Oxidation-Reduction; Oxidopamine; Oxygen; Phytic Acid; Sodium Compounds; Thermodynamics; Vanadium | 2001 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; Chromatography, High Pressure Liquid; Deferoxamine; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Homovanillic Acid; Iron; Iron Chelating Agents; Levodopa; Male; Motor Activity; Neurodegenerative Diseases; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperazines; Quinolines; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |
Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases.
Topics: Adrenergic Agents; Animals; Brain; Cell Line; Cell Survival; Deferoxamine; Dose-Response Relationship, Drug; Drug Interactions; Humans; In Vitro Techniques; Metals; Neuroprotective Agents; Oligopeptides; Oxidative Stress; Oxidopamine; Rats; Siderophores; Thiobarbituric Acid Reactive Substances | 2006 |
Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Deferoxamine; Disease Models, Animal; Dopamine; Drug Therapy, Combination; Glutathione; Male; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidopamine; Parkinson Disease; Protein Carbonylation; Quercetin; Rats; Rats, Sprague-Dawley; Reaction Time; Superoxide Dismutase | 2013 |
Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Apomorphine; Deferoxamine; Dopamine Agonists; Dopaminergic Neurons; Functional Laterality; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Photomicrography; Rats, Long-Evans; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease.
Topics: Animals; Brain; Curcumin; Deferoxamine; Disease Models, Animal; Dopamine; Drug Interactions; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2014 |
Iron chelator Deferoxamine protects human neuroblastoma cell line SH-SY5Y from 6-Hydroxydopamine-induced apoptosis and autophagy dysfunction.
Topics: Apoptosis; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Deferoxamine; Humans; Immunohistochemistry; Microscopy, Fluorescence; Neuroblastoma; Oxidopamine; Reactive Oxygen Species | 2020 |
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Topics: Animals; Catecholamines; Deferasirox; Deferiprone; Deferoxamine; Dopamine; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Oxidopamine; PC12 Cells; Rats | 2022 |